Clinical Trial Update: Lenvatinib Plus Sintilimab in Patients With Immune Checkpoint Inhibitor Previously Treated Advanced Liver Cancer [Phase 2]

View source ↗

Summary

This clinical trial update reports a Phase 2 study evaluating the combination of lenvatinib and sintilimab for advanced liver cancer (intrahepatic cholangiocarc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Intrahepatic Cholangiocarcinoma

Drugs mentioned

• LENVIMA (lenvatinib)
• Sintilimab (sintilimab)

Snippet

Sponsor: Fudan University | Conditions: Intrahepatic Cholangiocarcinoma | Phase 2 | Status: RECRUITING